MedTrace Logo

Myocardial Protection With Adenosine Preconditioning

NCT00881686 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 238

Last updated 2009-04-15

No results posted yet for this study

Summary

Adenosine has been proved to be an important mediator of myocardial protection induced by ischemic preconditioning. The hypothesis of this study is that adenosine preconditioning can provide additional myocardial protection in the setting of pediatric open heart surgery with cardioplegia and cardiopulmonary bypass.

Conditions

  • Heart Defects, Congenital
  • Cardiac Surgical Procedures
  • Myocardial Reperfusion Injury
  • Adenosine

Interventions

DRUG

adenosine

1.5mg/Kg adenosine will be administered intravenously before surgery

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Zhenxiao Jin, MD · Xijing Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
1 Day
Max Age
24 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00881686 on ClinicalTrials.gov